Target intelligence / Profile preview

Human Papilloma Virus L1 protein (HPV L1)

Target
HPV L1
Molecular classification
Viral structural protein, Capsid protein, Antigen
01

Overview

The Human Papilloma Virus L1 protein is the major capsid protein of the Human Papilloma Virus (HPV), forming the primary structural framework of the non-enveloped icosahedral virion. It plays a critical role in the initial stages of infection by mediating viral attachment to host cell surface receptors, specifically heparan sulfate proteoglycans, on basal layer keratinocytes. The L1 protein possesses a unique ability to spontaneously self-assemble into highly immunogenic, non-infectious virus-like particles (VLPs) when expressed recombinantly. This property is exploited in the development of prophylactic vaccines, which induce the production of neutralizing antibodies that prevent viral entry and subsequent infection. Persistent infection with high-risk HPV types, largely characterized by their specific L1 sequences, is the primary cause of cervical, anal, and oropharyngeal cancers, while low-risk types cause genital warts.

Other names
Major capsid protein L1HPV major capsid proteinMCPLate protein L1
02

Mechanism of action

Induction of neutralizing antibodies against the L1 protein to prevent viral attachment and entry into host cells.

03

Biological functions

Viral attachment to host cellViral entry into host cellSelf-assembly into virus-like particles (VLPs)Encapsidation of viral DNABinding to heparan sulfate proteoglycans (HSPGs)Induction of neutralizing antibodies
04

Disease associations

Cervical cancerAnal cancerVulvar cancerVaginal cancerOropharyngeal cancerGenital wartsHuman papillomavirus infection
05

Safety considerations

Injection site reactions (pain, swelling, redness)Syncope (fainting)Hypersensitivity to vaccine components (e.g., yeast proteins)Lack of therapeutic efficacy for existing infectionsType-specific protection limits (not all HPV types are covered by vaccines)
06

Interacting drugs

Recombinant Human Papillomavirus Quadrivalent Vaccine (Gardasil)

3 more in the full profile.

07

Biomarkers

Anti-HPV L1 antibodiesType-specific HPV DNAL1 protein expression in cytology

Beyond the preview

Go deeper on Human Papilloma Virus L1 protein (HPV L1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human Papilloma Virus L1 protein (HPV L1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call